Can Tyco Healthcare Go It Alone?

There's little argument that over the past several years, Tyco International has emerged as a powerhouse in the hospital supply and medical device industries through aggressive deal-making and a creative leveraging strategy that has enabled it to increase profits even in price-sensitive markets. Now Tyco, under pressure from fall-out over the scandal engulfing Enron, is breaking up in an effort to restore investor confidence and value. Some time in the future, Tyco Healthcare will operate as a stand-alone company. Yet questions loom large as to how well Tyco's strategy will play with the investment community, with some industry executives believing Tyco Healthcare has more value broken-up than as a public company.

There's little argument that over the past several years, Tyco International Ltd. has emerged as a powerhouse in the hospital supply and medical device industries. Through aggressive deal-making—it has bought up several of its most important rivals in hospital supply—and a creative leveraging strategy that has enabled it to increase profits even in price-sensitive markets, Tyco has been the 800-pound gorilla in medical supply. (See "What Makes Tyco Run?" IN VIVO, March 1999 [A#1999800050.) Moreover, as the leading force in hospital supply consolidation, its growth has come virtually at everyone else's expense. As it has gobbled up one competitor after another, it seems, the bigger Tyco has grown, the smaller everyone else has gotten, in both absolute and relative terms.

For the past several years, Tyco Healthcare Group LP has been one of Tyco's best performing businesses, but it has...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By 

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By 

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By 

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By 

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.